High burden of infections in Indian patients with Idiopathic Inflammatory Myopathy: validation of observations from the MyoCite dataset

被引:11
作者
Chatterjee, Rudrarpan [1 ]
Mehta, Pankti [1 ]
Agarwal, Vikas [1 ]
Gupta, Latika [1 ]
机构
[1] Sanjay Gandhi Post Grad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow 226014, Uttar Pradesh, India
关键词
idiopathic inflammatory myopathy; infections; opportunistic infections; tuberculosis; risk factors; PM; DM; OPPORTUNISTIC INFECTIONS; TUBERCULOSIS INFECTION; DERMATOMYOSITIS; POLYMYOSITIS; MYOSITIS; DISEASES; COHORT;
D O I
10.1093/rheumatology/keab015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective To determine the prevalence, profile and predictors of infections in an Indian cohort with idiopathic inflammatory myopathies (IIM). Methods We reviewed the records of a retrospective cohort with IIM enrolled from consecutive patients being followed up in the clinic, and these constituted the observation cohort. A newly diagnosed inception cohort with IIM were followed prospectively as the validation cohort for confirmation of observations and comparison with the observation cohort. Results Among the 68 patients in the observation cohort (average age 33.4years, female:male 4.2:1), 37 (54.4%) experienced 54 infections between them; of these 54 infections, 21 (38.8%) were major and recurrent infections and they occurred in 11 patients (16.17%) over 3.08years. Tuberculosis was the most common infection (12, 22.2%), with a predominance of extrapulmonary forms. Serum protein [odds ratio (OR) 0.44], platelets (0.44) at disease onset and daily steroid dose (1.04) predicted major infections on multivariate analysis. A higher daily dose of steroids at first infection correlated with number of recurrent infections. The infection-free 1-year survival was 73.8%. Of the 70 patients in the validation cohort (average age 35.7years, female:male 3.7:1), 3 had myositis attributed to an infection. A similar proportion of the cohort experienced infections (22, 33.3%) with similar number of major (10, 45.4%) and recurrent (4, 18%) infections being recorded. The most common infection was community-acquired pneumonia, followed by tuberculosis, with serum albumin (OR 0.25) at disease onset being the only predictor. The one-year infection-free survival rate was 64.7%. Those who had a major infection had increased mortality at 1year, with a survival rate of 60%, compared with 89.09% in those without. In both cohorts, a daily prednisone dose >6.25mg predisposed to major infections. Conclusion Major and recurrent infections are common in Indian IIM patients and confer higher risk for future infections and lower survival. Respiratory and atypical bacterial infections such as tuberculosis occur throughout the disease course.
引用
收藏
页码:4315 / 4326
页数:12
相关论文
共 41 条
  • [1] POLYMYOSITIS AND DERMATOMYOSITIS .2.
    BOHAN, A
    PETER, JB
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1975, 292 (08) : 403 - 407
  • [2] Bottai M, 2017, RMD OPEN, V3, DOI 10.1136/rmdopen-2017-000507
  • [3] Infections in polymyositis and dermatomyositis: analysis of 192 cases
    Chen, I-Jung
    Tsai, Wen-Pin
    Wu, Yeong-Jian Jan
    Luo, Shue-Fen
    Ho, Huei-Huang
    Liou, Lieh-Bang
    Chen, Ji-Yih
    Kuo, Chang-Fu
    Chang, Hsiao-Chun
    Yang, Chung-Han
    Yu, Kuang-Hui
    [J]. RHEUMATOLOGY, 2010, 49 (12) : 2429 - 2437
  • [4] TUBERCULOUS INFECTION OF SKELETAL-MUSCLE IN A CASE OF DERMATOMYOSITIS
    DAVIDSON, GS
    VOORNEVELD, CR
    KRISHNAN, N
    [J]. MUSCLE & NERVE, 1994, 17 (07) : 730 - 732
  • [5] World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
    Di Angelantonio, Emanuele
    Kaptoge, Stephen
    Pennells, Lisa
    De Bacquer, Dirk
    Cooney, Marie Therese
    Kavousi, Maryam
    Stevens, Gretchen
    Riley, Leanne
    Savin, Stefan
    Altay, Servet
    Amouyel, Philippe
    Assmann, Gerd
    Bell, Steven
    Ben-Shlomo, Yoav
    Berkman, Lisa
    Beulens, Joline W.
    Bjorkelund, Cecilia
    Blaha, Michael J.
    Blazer, Dan G.
    Bolton, Thomas
    Bonita, Ruth
    Brenner, Beaglehole Hermann
    Brunner, Eric J.
    Casiglia, Edoardo
    Chamnan, Parinya
    Choi, Yeun-Hyang
    Chowdhury, Rajiv
    Coady, Sean
    Crespo, Carlos J.
    Cushman, Mary
    Dagenais, Gilles R.
    D'Agostino, Ralph B.
    Daimon, Makoto
    Davidson, Karina W.
    Engstrom, Gunnar
    Fang, Xianghua
    Ford, Ian
    Gallacher, John
    Gansevoort, Ron T.
    Gaziano, Thomas Andrew
    Giampaoli, Simona
    Grandits, Greg
    Grimsgaard, Sameline
    Grobbee, Diederick E.
    Gudnason, Vilmundur
    Guo, Qi
    Humphries, Steve
    Iso, Hiroyasu
    Jukema, J. Wouter
    Kauhanen, Jussi
    [J]. LANCET GLOBAL HEALTH, 2019, 7 (10): : E1332 - E1345
  • [6] Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment
    Gaitonde, S
    Pathan, E
    Sule, A
    Mittal, G
    Joshi, VR
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 (03) : 251 - 253
  • [7] Pleural tuberculosis under rituximab therapy for anti-synthetase syndrome
    Gazaix-Fontaine, E.
    Ottaviani, S.
    Dieude, P.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2018, 47 (04) : 338 - 339
  • [8] HIGH PREVALENCE OF TUBERCULOSIS IN ADULTS AND CHILDREN WITH IIM AS COMPARED WITH SLE: RETROSPECTIVE DATA REVIEW FROM A LARGE COHORT AT A TERTIARY CARE CENTER IN INDIA.
    Gupta, L.
    Zanwar, A.
    Aggarwal, R.
    Lawrence, A.
    Misra, D.
    Agarwal, V.
    Misra, R.
    Aggarwal, A.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1583 - 1584
  • [9] Meeting report: MyoIN - Pan-India Collaborative Network for Myositis Research
    Gupta, Latika
    Appani, Sravan Kumar
    Janardana, Ramya
    Muhammed, Hafis
    Lawrence, Able
    Amin, Sanjiv
    Shobha, Vineeta
    Rajasekhar, Liza
    Misra, Ramnath
    [J]. INDIAN JOURNAL OF RHEUMATOLOGY, 2019, 14 (02) : 136 - 142
  • [10] Prevalence and predictors of asymptomatic vertebral fractures in inflammatory myositis
    Gupta, Latika
    Lawrence, Able
    Edavalath, Sukesh
    Misra, Ramnath
    [J]. INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2018, 21 (03) : 725 - 731